Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

RotaTeq

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

By Emily Morton-West

Amiculum

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

A Call to Action: Bridging the Adult Immunization Divide

Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

Medscape Education

- PMLiVE

David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

- PMLiVE

GSK shares promising phase 3 results for linerixibat in PBC-related itch

Pruritus is experienced by up to 90% of patients with the rare liver disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links